A detailed history of Headlands Technologies LLC transactions in Genmab A/S stock. As of the latest transaction made, Headlands Technologies LLC holds 5,138 shares of GMAB stock, worth $118,790. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,138
Previous 285 1702.81%
Holding current value
$118,790
Previous $8,000 1512.5%
% of portfolio
0.01%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

BUY
$25.13 - $30.27 $121,955 - $146,900
4,853 Added 1702.81%
5,138 $129,000
Q1 2024

May 07, 2024

BUY
$26.43 - $32.77 $7,532 - $9,339
285 New
285 $8,000
Q3 2023

Nov 09, 2023

BUY
$35.27 - $42.24 $27,228 - $32,609
772 New
772 $27,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $15.2B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Headlands Technologies LLC Portfolio

Follow Headlands Technologies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Headlands Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Headlands Technologies LLC with notifications on news.